Zetia vs. Leqvio

See how Zetia and Leqvio compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Zetia is a once-daily pill that blocks cholesterol absorption in the gut, while Leqvio is an injection that silences PCSK9 production in the liver just twice a year after starting doses.

  • Leqvio generally produces larger LDL-C reductions than Zetia, but it requires a clinician-administered injection instead of a pill you take at home.

  • Zetia has been available as an affordable generic since the mid-2010s, while Leqvio is a newer injectable therapy usually reserved for patients who need additional LDL lowering.

Zetia vs. Leqvio Drug Summary

Zetia

Zetia (ezetimibe) is a cholesterol absorption inhibitor used to lower LDL cholesterol in adults and certain adolescents with high cholesterol. It's taken as a once-daily oral tablet, either alone or combined with a statin or fenofibrate.

Leqvio

Leqvio (inclisiran) is a PCSK9 synthesis inhibitor that uses siRNA technology to lower LDL cholesterol in adults and adolescents with hypercholesterolemia. It's given as a subcutaneous injection on Day 1 and Day 90, then just twice a year for maintenance.

Zetia vs. Leqvio Side Effects

Zetia

Most common
Upper respiratory tract infection (up to 4.3%)
Diarrhea (up to 4.1%)
Arthralgia (up to 3.0%)

Leqvio

Most common
Injection site reaction (3% or more)
Arthralgia (3% or more)
Bronchitis (3% or more)

Zetia vs. Leqvio Dosage

Zetia

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily At the start
Maximum dose 10 mg once daily Same as starting
Dose changes None Fixed dose

Leqvio

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 284 mg injection Day 1
Maximum dose 284 mg injection Same as starting
Dose changes None Fixed dose

Zetia vs. Leqvio Indications

Zetia

Zetia is FDA-approved to lower LDL cholesterol as an add-on to diet, either alone or with a statin, in adults with primary hyperlipidemia. It's also approved for certain inherited high-cholesterol conditions, including familial hypercholesterolemia starting at age 10.

  • Lowers LDL-C in adults with primary hyperlipidemia, alone or with a statin

  • Used with a statin for heterozygous familial hypercholesterolemia (age 10+)

  • Combined with fenofibrate for mixed hyperlipidemia

  • Combined with a statin for homozygous familial hypercholesterolemia (age 10+)

Leqvio

Leqvio is FDA-approved to lower LDL cholesterol as an add-on to diet and exercise in adults with hypercholesterolemia. It's also approved for heterozygous and homozygous familial hypercholesterolemia in patients aged 12 and older.

  • Lowers LDL-C in adults with hypercholesterolemia

  • Used for heterozygous familial hypercholesterolemia (age 12+)

  • Approved for pediatric homozygous familial hypercholesterolemia (age 12+)

  • Not approved for adults with homozygous familial hypercholesterolemia

Zetia vs. Leqvio Pros and Cons

Zetia

Zetia works by blocking cholesterol absorption in the gut, giving it a mechanism distinct from statins and PCSK9 therapies. It's inexpensive as a generic and easy to take, though its LDL-lowering effect is more modest than newer injectable options.

Pros

  • Oral pill, no injections needed

  • Available generically and widely covered by insurance

  • Long track record, on the market since 2002

  • Can be combined with a statin or fenofibrate for added LDL lowering

Cons

  • Must be taken every day to stay effective

  • Produces smaller LDL reductions than PCSK9-targeted therapies

  • Requires liver enzyme monitoring when combined with a statin

  • Not approved as monotherapy for homozygous familial hypercholesterolemia

Leqvio

Leqvio blocks PCSK9 production in the liver using siRNA technology, delivering strong LDL reductions with just two injections a year after the starting doses. It must be given by a healthcare provider and has a shorter track record than oral options like Zetia.

Pros

  • Only two maintenance injections per year after starting doses

  • Produces larger average LDL-C reductions than ezetimibe

  • Newer siRNA mechanism, silences PCSK9 production in the liver

  • No daily pill to remember

Cons

  • Must be given by a healthcare provider via injection

  • Approved more recently (2021), with less long-term real-world data

  • Injection site reactions are common

  • Not approved for adults with homozygous familial hypercholesterolemia

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.